Ebola Vaccine Trial Launches in DRC Amidst Outbreak

The first clinical trial of an Ebola vaccine in the Democratic Republic of Congo (DRC) began on October 23, 2026. Headed by the World Health Organization, the trial, named Tumaini (Swahili for 'hope'), commenced with the first vaccination administered in Bunia, Ituri province. This initiative is critical as the DRC grapples with its worst-ever Ebola outbreak, which has surpassed 9,700 cases and over 4,600 deaths.

The Tumaini trial is designed to assess whether Ervebo, a vaccine effective against the Zaire strain, can provide cross-protection against the Bundibugyo strain. This species of Ebola is responsible for the current epidemic, and no approved vaccines or treatments were previously available for it. The trial framework is adaptable and is preparing to incorporate two candidate vaccines specifically for the Bundibugyo strain, developed by the University of Oxford and Moderna.

This trial represents a significant step towards combating the epidemic, especially by including pregnant women and children aged 12 and above. Success could lead to the first proven efficacy data against the Bundibugyo virus, transforming outbreak response and preparedness for future events. The WHO is supporting this DRC-led effort, aiming to generate robust evidence to curtail the epidemic and save lives.